Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLASH: SGX301 in Cutaneous T-Cell Lymphoma
NCT02448381Phase 3Completed
- Sponsor
- Soligenix
- Start
- Dec 2015
- Primary completion
- Jun 2020
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of hypericin in cutaneous T-cell lymphoma (CTCL), sponsored by Soligenix. Started Dec 2015; status: completed.
02
Drugs
hypericin
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02448381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02448381.